Core Insights - Lisata Therapeutics, Inc. is set to report its financial results for Q3 2025 on November 6, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern time [1] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company's lead product candidate, certepetide, is designed to enhance the delivery of anti-cancer drugs to solid tumors through a novel uptake pathway [3] - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [3] - The company anticipates announcing multiple milestones over the next 1.5 years and projects that its capital will support operations into Q1 2027, including data milestones from ongoing clinical trials [3]

Group 1 - Lisata Therapeutics will present a corporate overview at the LD Micro Main Event XIX Conference in San Diego from October 19-21, 2025 [1][3] - The presentation is scheduled for October 20th at 10:30 a.m. Pacific time, with opportunities for one-on-one meetings throughout the conference [2] - The LD Micro Main Event XIX will feature around 120 companies presenting and conducting private meetings with investors [3] Group 2 - Lisata Therapeutics is focused on developing innovative therapies for advanced solid tumors and other serious diseases, with its lead product candidate, certepetide, designed to enhance the targeting of anti-cancer drugs [4] - The company has established significant commercial and R&D partnerships based on its CendR Platform® technology and anticipates announcing multiple milestones over the next 1.5 years [4] - Lisata expects its projected capital to fund operations through the fourth quarter of 2026, including anticipated data milestones from ongoing and planned clinical trials [4]